• Obtained European Union patent 2014 for a new treatment for unipolar depression. • Pursuing U.S. patent.• Pursued activities to advance the commercial interests of my patents.• Currently, designing preclinical, pharmacokinetic and/or biomarker studies as follow-up to the positive open clinical study in unipolar depression I performed at Harvard.• Home business activities will not interfere with a full-time position.

Director, Clinical Development• Directed two pivotal Phase III studies in Cognitive Impairment Associated with Schizophrenia (CIAS) within multidisciplinary teams, working in close collaboration with Pharmacokinetics, Statistics, Safety, Regulatory, Clinical Operations, KOLs and vendors. • Directly involved in recruitment and management of Investigators for the large global Phase III studies. • Directly involved in improvement of study subject recruitment, selection and management. • Chief Medical Monitor overseeing CRO Medical Monitors for the global Phase III studies. • Developed multiple blinded study data metrics to monitor quality of the Phase III data. • Direct involvement in Phase I study design and protocol development, as well as necessary Investigator and KOL consultations. • Primary author in development of a novel Phase IIa Proof-of-Concept (POC) study for schizophrenia indication. • Primary author in development of a Phase IIb study for difficult to study schizophrenia indication. • Constructed clinical development plans with specific GO-NO GO criteria for compounds in CNS indications. • Key role in selecting new indications for existing compounds in development, in collaboration with preclinical scientists, others in Clinical Development, Commercial and Regulatory. • Direct involvement in generating initial submissions and responses to queries for regulatory authorities in the U.S. and worldwide. • Provided education for study Investigators at Investigator Meetings and for Site Monitors at in-house seminars.

• Participated in the design, and wrote and directed Phase IIb and Phase III clinical studies for multiple indications in psychiatry (schizophrenia, bipolar, depression, anxiety) within multidisciplinary teams, working in close collaboration with Pharmacokinetics, Statistics, Safety, Regulatory, Clinical Operations, KOLs and vendors. • Developed multiple blinded study data metrics to monitor quality of the Phase IIb data, and determined minimal clinically meaningful improvement necessary for positive study by in-depth analyses of all public competitor studies. • Was the supervising Medical Monitor overseeing in-house and CRO Medical Monitors for the global Phase IIb and Phase III studies. • Directly involved in improvement of study subject recruitment, selection and management. • Direct involvement in generating initial submissions and responses to queries for regulatory authorities in the U.S. and worldwide. • Central role in determining that proposed new psychiatric diagnosis should not be pursued as a new indication for existing product, in collaboration with preclinical scientists, others in Clinical Development, Commercial and Regulatory. Provided education for study Investigators at Investigator Meetings and for Site Monitors at in-house seminars.

• Worked closely within multidisciplinary teams of preclinical scientists, Clinical Medicine, Pharmacokinetics, Statistics, Safety, Regulatory, Commercial and Clinical Operations, as well as KOLs and vendors, for Phase I and Phase IIa studies for compounds developed for CNS indications, such as Alzheimer’s Disease (symptomatic and disease-modifying compounds), autism, bipolar disorder, CIAS, depression and schizophrenia.• In Translational Medicine, was responsible for developing plans for Proof-of-Mechanism for an average of 10 compounds at a time, and designed, wrote and directed many preclinical and Phase 1 healthy volunteer studies to establish Proof-of-Mechanism via biomarkers. Responsible for designing, writing and performing Methods studies for biomarkers new to the company.• In Clinical Medicine, participated in the designs, and wrote and directed Phase I First-in-Human single and multiple dose, Phase I First-in-Patient, and Phase IIa POC studies. • Prepared clinical development plans for compounds across multiple CNS indications. • Collaborated in evaluation of in-licensing opportunities.• Was Medical Monitor for multiple clinical studies across multiple CNS indications.• Managed collaborations with Investigators, KOLs, academic institutions and foundations.

Assistant Professor at the Harvard Medical School.Wrote and directed Phase 2, 3 and 4 psychopharmacological studies for affective disorder patients, as well as collaborated in studies in schizophrenia and anxiety disorders. Developed a new treatment for unipolar depression utilizing nutritional supplements, (U.S. patent filed and European patent approved). Sought IRB approval for studies under my direction, and served as IRB member. Provided evaluation and ongoing treatment of outpatients suffering from psychiatric disorders, specializing in the evaluation and care of bipolar disorder patients. Taught psychiatry residents, including yearlong lecture series on psychopharmacology and yearlong lecture series psychiatric research methods.

Assistant Professor at the Harvard Medical School.Supervised a 17 bed locked inpatient psychiatry unit in a public hospital caring for the seriously mentally ill. Reduced average length of stay from 28 days to 12 days with no increase in readmission rates and no increase in post-discharge suicide attempt rates. Evaluated and cared for psychiatric inpatients. Taught and supervised psychiatry residents, Harvard Medical School students and social work interns in patient care, case conferences and psychopharmacology lectures.

Associate Professor, Boston University School of Medicine.Supervised a 20 bed locked inpatient geriatric psychiatry unit, outpatient geriatric partial program, and outpatient geriatric psychiatric care. Initiated programs for evaluating and improving quality of care. Initiated programs for psychiatry resident and medical student rotations in psychiatry. Taught psychiatry residents, including lecture series on psychopharmacology.

Associate Professor, Boston University School of MedicineSupervised two 28 bed locked inpatient psychiatry units and numerous outpatient psychiatry clinics. Contributed significantly to regional VA hospital strategic planning. Initiated successful programs to reduce assaults committed on inpatient units. Taught psychiatry residents, including lecture series on psychopharmacology.